ReviewJournal of thrombosis and thrombolysis2016
Guidance for the treatment of deep vein thrombosis and pulmonary embolism.
Review in Journal of thrombosis and thrombolysis, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 137 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
137 citing papers in PubMed, 5 syntheses or guidelines pooled it, 339 citations in OpenAlex.
- Statins for adults with a first episode of venous thromboembolic disease.The Cochrane database of systematic reviews · 2026Pooled it
- Pharmacological interventions for preventing venous thromboembolism in people undergoing bariatric surgery.The Cochrane database of systematic reviews · 2022Pooled it
- American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism.Blood advances · 2020Guideline
- Treatment of distal deep vein thrombosis.The Cochrane database of systematic reviews · 2020Pooled it
- Pooled it
- A Single-Center, Randomized, Double-Blind Study of 94 Patients Undergoing Surgery for Cerebral Glioma to Compare Postoperative Thromboprophylaxis with and without Rivaroxaban.Medical science monitor : international medical journal of experimental and clinical research · 2022Trial
- First Evidence: TRAP-Induced Platelet Aggregation Is Reduced in Patients Receiving Xabans.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis · 2018Trial
- Association between D-dimer difference and risk of postoperative venous thromboembolism in endometrial cancer: a retrospective cohort study.Thrombosis journal · 2026Article
- Risk Stratification in Pulmonary Embolism: The Expanding Role of Biomarkers.Biomedicines · 2026Review
- Deep vein thrombosis and coagulopathy following cyclone events: pathophysiology, risk factors, and prevention.Annals of medicine and surgery (2012) · 2026Review
- Risk Factors and Clinical Outcomes for Patients with Venous Thromboembolism in Kenya: Findings from the HEART Registry.Vascular health and risk management · 2026Article
- Unraveling the cardiovascular burden of long COVID: symptom profiles, underlying mechanisms, and clinical management insights.Frontiers in cardiovascular medicine · 2026Review
- The clot cases conference: a proposed model to enhance multidisciplinary thrombosis care.Journal of thrombosis and thrombolysis · 2026Article
- Anticoagulation in malignancy: the patient who bleeds and clots simultaneously.Hematology. American Society of Hematology. Education Program · 2025Review
- Anticoagulant therapy in patients with cancer and thrombocytopenia.Journal of thrombosis and thrombolysis · 2025Review
- Asundexian: a systematic review of safety, efficacy, and pharmacological insights in thrombosis.Thrombosis journal · 2025Review
- Article
- Hyperuricemia is a prognostic marker for antiphospholipid syndrome patients: a retrospective cohort study in China.Clinical rheumatology · 2025Article
- The predicted value for venous thromboembolism based on a modified model of caprini combined with fasting blood glucose and D-dimer: a retrospective study.BMC musculoskeletal disorders · 2025Article
- Anticoagulants utilization in eight hospitals within the Luzhou region from 2019 to 2023.PloS one · 2025Article
77 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issued
Authors and funding
9 authors at 9 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This guidance document focuses on the diagnosis and treatment of venous thromboembolism (VTE). Efficient, cost effective diagnosis of VTE is facilitated by combining medical history and physical examination with pre-test probability models, D dimer testing and selective use of confirmatory imaging. Clinical prediction rules, biomarkers and imaging can be used to tailor therapy to disease severity. Anticoagulation options for acute VTE include unfractionated heparin, low molecular weight heparin, fondaparinux and the direct oral anticoagulants (DOACs). DOACs are as effective as conventional therapy with LMWH and vitamin K antagonists. Thrombolytic therapy is reserved for massive pulmonary embolism (PE) or extensive deep vein thrombosis (DVT). Inferior vena cava filters are reserved for patients with acute VTE and contraindications to anticoagulation. Retrievable filters are strongly preferred. The possibility of thoracic outlet syndrome and May-Thurner syndrome should be considered in patients with subclavian/axillary and left common iliac vein DVT, respectively in absence of identifiable triggers. The optimal duration of therapy is dictated by the presence of modifiable thrombotic risk factors. Long term anticoagulation should be considered in patients with unprovoked VTE as well as persistent prothrombotic risk factors such as cancer. Short-term therapy is sufficient for most patients with VTE associated with transient situational triggers such as major surgery. Biomarkers such as D dimer and risk assessment models such the Vienna risk prediction model offer the potential to customize VTE therapy for the individual patient. Insufficient data exist to support the integration of bleeding risk models into duration of therapy planning.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.